|
Aptamer Group PLC - York, England-based synthetic binders developer - Wins new contract with a ‘top five pharmaceutical company’ with a value of up to £617,000. It says the contract is the third with this pharmaceutical company and represents ‘strong validation’ of the Optimer platform. Under the agreement, Aptamer will develop Optimer binders against three key drug targets. Further, Aptamer will provide critical support for ELISA assay development. ‘These tools will enable the partner to validate drug candidates and may also be used to analyse patient samples during clinical trials, potentially leading to clinical diagnostic development,’ Aptamer says. Aptamer retains full intellectual property rights to all developed Optimers. It has a total signed contract value of £1.8 million, up 46% from £1.2 million at the same time last year. ‘This contract represents significant commercial validation and increasing traction of our Optimer technology platform,’ says Chief Executive Officer Arron Tolley. ‘We are well-positioned to build on last year’s performance and deliver sustained revenue growth. We continue to build a robust foundation of repeat business with leading pharmaceutical partners, converting our commercial pipeline into long-term value for shareholders.’ Current stock price: 0.85 pence, up 6.1% on Tuesday afternoon in London 12-month change: up sharply from 0.23p on November 4, 2024 Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
